Glaukos inks exclusive license with RevOpsis for RO-104
Glaukos said it has entered an exclusive licensing agreement with RevOpsis Therapeutics to develop and commercialize RO-104 for retinal diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.